PRELUDE THERAPEUTICS INC (PRLD)
Health Care · Clinical-stage biopharmaceuticals · NASDAQ
An early-stage biopharma company developing novel small-molecule drug candidates targeting protein-driven disease mechanisms.
What PRELUDE THERAPEUTICS INC does
Prelude Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel drug candidates using its proprietary understanding of protein function and disease biology. The company is pursuing multiple therapeutic programs across different disease areas, with a focus on first-in-class and best-in-class opportunities. As of Q1 2026, Prelude reported its first revenue of $4.58 million, indicating progress toward commercialization or partnership milestones. The company remains unprofitable with significant R&D spending as it advances its pipeline through clinical development and regulatory approval pathways.
Themes: ["Clinical-stage drug development"]
Fundamentals
- Price$4.91 as of 2026-07-09 close
- Market cap$391M as of 2026-07-10
- 1-year return+507.8% as of 2026-07-09 close
- Net margin-278.5% as of 2026-07-10
- ROE-74.6% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+41.0% as of 2026-07-10
- Beta0.92 as of 2026-07-10
Key risks (from latest filing)
["Company has incurred significant operating losses since inception and expects continued losses for the foreseeable future, with no guarantee of ever achieving profitability despite current revenue recognition."]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.